Protara Therapeutics, Inc.
TARAProtara Therapeutics, Inc. in brief
Protara Therapeutics, Inc. is a listed company in the Biotechnology industry, based in New York, New York, USA. Its market value was $235 M on 1 August 2026, which makes it the 15,679th largest listed company in the world and the 3,057th largest in the USA on this site. It employs about 51 people and Jesse Shefferman is its chief executive. Its shares trade under the symbol TARA (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Protara Therapeutics, Inc.
We are a New York City based clinical-stage biopharmaceutical company committed to advancing transformative therapies for the treatment of cancer and rare diseases. We were founded on the principle of applying modern scientific, regulatory or manufacturing advancements to established mechanisms in order to create new development opportunities. We prioritize creativity, integrity and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options.
Our portfolio includes two development programs utilizing TARA-002, an investigational cell therapy based on the broad immunopotentiator, OK-432, which was originally granted marketing approval by the Japanese Ministry of Health and Welfare as an immunopotentiating cancer therapeutic agent. This cell therapy is currently approved in Japan and Taiwan for lymphatic malformations, or LMs, and multiple oncologic indications. We have secured worldwide rights to the asset excluding Japan and Taiwan and are exploring its use in oncology and rare disease indications. TARA-002 was developed from the same master cell bank of genetically distinct group A Streptococcus pyogenes as OK-432 (marketed as Picibanil® in Japan by Chugai Pharmaceutical Co., Ltd., or Chugai Pharmaceutical). We are currently developing TARA-002 in non-muscle invasive bladder cancer, or NMIBC, and LMs. We are also pursuing IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
From the company's annual report filed with the US SEC: read the report
Protara Therapeutics, Inc. timeline
- 2006
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2014
- 🔔Initial public offering as Proteon Therapeutics IncFinal prospectus filed with the SEC on 22 October 2014; shares registered for exchange trading on 16 October 2014.
- 2019
- ✎Renamed ArTara Therapeutics, Inc.Formerly Proteon Therapeutics Inc.
- 2020
- ✎Renamed Protara Therapeutics, Inc.Formerly ArTara Therapeutics, Inc..
Events of Protara Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,689 (Jan 2022) · #5,066 (Dec 2022) · #5,026 (Jul 2023) · #4,310 (Jan 2024) · #1,521 (Mar 2026) · #3,020 (Aug 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 1.2×
- Free cash flow yield
- -24.0%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -29.2%
- Liabilities / assets
- 6.2%
- R&D / revenue
- 218.0%
- Profit per employee
- $-1.1 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-65M | $-57M | — |
| Dec 2024 | — | — | $-49M | $-45M | — |
| Dec 2023 | — | — | $-44M | $-40M | — |
| Dec 2022 | — | — | $-67M | $-66M | — |
| Dec 2021 | — | — | $-47M | $-47M | — |
| Dec 2020 | — | — | $-34M | $-34M | — |
| Dec 2019 | — | — | $-8M | $-8M | — |
| Dec 2018 | — | — | $-21M | $-21M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-56M | $0M | $-56M | $-1.34 | — |
| Dec 2024 | $-36M | $0M | $-36M | $-2.17 | — |
| Dec 2023 | $-38M | $0M | $-38M | $-3.57 | — |
| Dec 2022 | $-26M | $0M | $-27M | $-5.86 | — |
| Dec 2021 | $-35M | $1M | $-35M | $-4.21 | — |
| Dec 2020 | $-23M | $1M | $-24M | $-4.70 | — |
| Dec 2019 | $-5M | $0M | $-5M | $-3.04 | — |
| Dec 2018 | $-23M | $0M | $-23M | $-45.80 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-22M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 6, 202610-QQuarterly report · period to Sep 2026
- Nov 6, 20268-KCurrent reportResults of operations
- Aug 11, 202610-QQuarterly report · period to Jun 2026
- Aug 11, 20268-KCurrent reportResults of operations
- Jun 29, 20268-KCurrent reportDirectors or officers changed
- Jun 15, 20268-KCurrent reportShareholder vote
- May 13, 202610-QQuarterly report · period to Mar 2026
- May 13, 20268-KCurrent reportResults of operations
- Apr 28, 2026DEF 14AProxy statement
- Mar 30, 20268-KCurrent reportRegulation FD disclosure
- Mar 10, 202610-KAnnual report · period to Dec 2025
- Mar 10, 20268-KCurrent reportResults of operations
Official filings of Protara Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-65 M
- Net income
- $-57 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $209 M
- Total liabilities
- $13 M
- Total equity
- $196 M
As of December-2025
Top 100 institutional investors in Protara Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 3,706,130 | +42,631 (+1.16%) | 6.02% | $11 M | Nov 13, 2026 |
| 2 | Millennium Management LLC | 3,097,095 | -4,071 (-0.13%) | 5.03% | $9 M | Nov 16, 2026 |
| 3 | Velan Capital Investment Management LP | 2,844,652 | 0 (0.00%) | 4.62% | $9 M | Nov 16, 2026 |
| 4 | Rosalind Advisors, Inc. | 2,400,000 | New | 3.90% | $7 M | Nov 16, 2026 |
| 5 | Blackstone Inc. | 2,366,514 | +101,000 (+4.46%) | 3.84% | $7 M | Nov 16, 2026 |
| 6 | Vanguard Capital Management LLC | 2,300,133 | 0 (0.00%) | 3.74% | $7 M | Nov 13, 2026 |
| 7 | Citadel Advisors LLC | 2,087,107 | +854,742 (+69.36%) | 3.39% | $6 M | Nov 16, 2026 |
| 8 | Sio Capital Management, LLC | 1,991,339 | +69,467 (+3.61%) | 3.23% | $6 M | Nov 16, 2026 |
| 9 | Baker Bros. Advisors LP | 1,843,795 | +872,181 (+89.77%) | 2.99% | $6 M | Nov 16, 2026 |
| 10 | Acorn Capital Advisors, LLC | 1,752,115 | 0 (0.00%) | 2.85% | $5 M | Nov 16, 2026 |
| 11 | Marshall Wace, LLP | 1,543,284 | +842,263 (+120.15%) | 2.51% | $5 M | Nov 13, 2026 |
| 12 | 5AM Venture Management, LLC | 1,369,782 | 0 (0.00%) | 2.22% | $4 M | Nov 16, 2026 |
| 13 | Geode Capital Management, LLC | 1,333,520 | +7,274 (+0.55%) | 2.17% | $4 M | Nov 6, 2026 |
| 14 | Integral Health Asset Management, LLC | 1,250,000 | -250,000 (-16.67%) | 2.03% | $4 M | Nov 16, 2026 |
| 15 | Qube Research & Technologies Ltd | 1,168,444 | +122,928 (+11.76%) | 1.90% | $4 M | Nov 13, 2026 |
| 16 | Ameriprise Financial Inc | 1,119,841 | +1,063,574 (+1890.23%) | 1.82% | $3 M | Nov 16, 2026 |
| 17 | State Street Corp | 1,048,080 | -20,215 (-1.89%) | 1.70% | $3 M | Nov 12, 2026 |
| 18 | Palo Alto Investors LP | 1,035,964 | New | 1.68% | $3 M | Nov 16, 2026 |
| 19 | Balyasny Asset Management L.P. | 1,003,180 | -23,511 (-2.29%) | 1.63% | $3 M | Nov 16, 2026 |
| 20 | Walleye Capital LLC | 933,246 | +427,814 (+84.64%) | 1.52% | $3 M | Nov 13, 2026 |
| 21 | Bank Of America Corp /de/ | 919,340 | +37,161 (+4.21%) | 1.49% | $3 M | Nov 16, 2026 |
| 22 | ADAR1 Capital Management, LLC | 850,512 | -90,000 (-9.57%) | 1.38% | $3 M | Nov 16, 2026 |
| 23 | Dimensional Fund Advisors LP | 684,093 | +863 (+0.13%) | 1.11% | $2 M | Nov 4, 2026 |
| 24 | Northern Trust Corp | 536,426 | -15,880 (-2.88%) | 0.87% | $2 M | Nov 16, 2026 |
| 25 | Renaissance Technologies LLC | 531,830 | +280,330 (+111.46%) | 0.86% | $2 M | Nov 12, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Catalio Capital Management, LP | 512,287 | -7,861 (-1.51%) | 0.83% | $2 M | Nov 16, 2026 |
| 27 | UBS Group AG | 373,239 | -83,534 (-18.29%) | 0.61% | $1 M | Nov 10, 2026 |
| 28 | Vanguard Portfolio Management LLC | 363,536 | -128,121 (-26.06%) | 0.59% | $1 M | Nov 13, 2026 |
| 29 | Vanguard Fiduciary Trust Co | 362,283 | +27,600 (+8.25%) | 0.59% | $1 M | Nov 13, 2026 |
| 30 | Verdad Advisers, LP | 352,002 | +39,753 (+12.73%) | 0.57% | $1 M | Nov 16, 2026 |
| 31 | Jane Street Group, LLC | 291,491 | New | 0.47% | $1 M | Nov 12, 2026 |
| 32 | HRT Financial LP | 290,961 | New | 0.47% | $1 M | Nov 13, 2026 |
| 33 | Two Sigma Investments, LP | 241,997 | +172,345 (+247.44%) | 0.39% | $1 M | Nov 16, 2026 |
| 34 | Oppenheimer & Co Inc | 217,631 | -20,731 (-8.70%) | 0.35% | $1 M | Oct 26, 2026 |
| 35 | Morgan Stanley | 211,030 | -297,404 (-58.49%) | 0.34% | $1 M | Nov 13, 2026 |
| 36 | Point72 Asset Management, L.P. | 205,272 | -343,660 (-62.61%) | 0.33% | $1 M | Nov 16, 2026 |
| 37 | Woodline Partners LP | 179,164 | New | 0.29% | $1 M | Nov 16, 2026 |
| 38 | XTX Topco Ltd | 175,722 | +111,774 (+174.79%) | 0.29% | $1 M | Nov 16, 2026 |
| 39 | Jump Financial, LLC | 173,600 | -29,500 (-14.52%) | 0.28% | $1 M | Nov 13, 2026 |
| 40 | Goldman Sachs Group Inc | 159,713 | -386,514 (-70.76%) | 0.26% | $0 M | Nov 16, 2026 |
| 41 | Charles Schwab Investment Management Inc | 157,252 | -719 (-0.46%) | 0.26% | $0 M | Nov 16, 2026 |
| 42 | CIBC World Market Inc. | 150,995 | -15,500 (-9.31%) | 0.25% | $0 M | Nov 10, 2026 |
| 43 | Bank of New York Mellon Corp | 142,939 | +5,250 (+3.81%) | 0.23% | $0 M | Nov 5, 2026 |
| 44 | Fisher Asset Management, LLC | 129,612 | +30,046 (+30.18%) | 0.21% | $0 M | Nov 6, 2026 |
| 45 | J. Goldman & Co LP | 108,000 | -27,000 (-20.00%) | 0.18% | $0 M | Nov 16, 2026 |
| 46 | Cary Street Partners Financial LLC | 100,000 | New | 0.16% | $0 M | Nov 12, 2026 |
| 47 | American Century Companies Inc | 98,145 | -342 (-0.35%) | 0.16% | $0 M | Nov 12, 2026 |
| 48 | FMR LLC | 84,656 | +16,456 (+24.13%) | 0.14% | $0 M | Nov 10, 2026 |
| 49 | Alps Advisors Inc | 77,735 | +20,694 (+36.28%) | 0.13% | $0 M | Nov 3, 2026 |
| 50 | Nuveen, LLC | 72,633 | +23 (+0.03%) | 0.12% | $0 M | Nov 10, 2026 |
| 51 | Bridgeway Capital Management, LLC | 69,830 | -15,500 (-18.16%) | 0.11% | $0 M | Nov 16, 2026 |
| 52 | Two Sigma Securities, LLC | 69,693 | New | 0.11% | $0 M | Nov 16, 2026 |
| 53 | Squarepoint Ops LLC | 68,685 | +50,561 (+278.97%) | 0.11% | $0 M | Nov 9, 2026 |
| 54 | D. E. Shaw & Co., Inc. | 66,005 | +54,892 (+493.94%) | 0.11% | $0 M | Nov 16, 2026 |
| 55 | Rhumbline Advisers | 65,337 | +2,092 (+3.31%) | 0.11% | $0 M | Nov 10, 2026 |
| 56 | Empowered Funds, LLC | 62,500 | New | 0.10% | $0 M | Nov 13, 2026 |
| 57 | Los Angeles Capital Management LLC | 62,225 | New | 0.10% | $0 M | Nov 12, 2026 |
| 58 | Truist Financial Corp | 60,000 | 0 (0.00%) | 0.10% | $0 M | Oct 30, 2026 |
| 59 | Nano Cap New Millennium Growth Fund L P | 57,500 | +7,500 (+15.00%) | 0.09% | $0 M | Nov 13, 2026 |
| 60 | Indivisible Partners | 51,124 | New | 0.08% | $0 M | Oct 26, 2026 |
| 61 | Deutsche Bank AG\ | 50,423 | -7,290 (-12.63%) | 0.08% | $0 M | Nov 6, 2026 |
| 62 | Quadrature Capital Ltd | 48,420 | +9,101 (+23.15%) | 0.08% | $0 M | Nov 13, 2026 |
| 63 | Price T Rowe Associates Inc /MD/ | 47,822 | +9,339 (+24.27%) | 0.08% | $0 M | Nov 16, 2026 |
| 64 | Odyssean, LLC | 44,205 | New | 0.07% | $0 M | Nov 16, 2026 |
| 65 | Axq Capital, LP | 41,904 | New | 0.07% | $0 M | Nov 12, 2026 |
| 66 | EntryPoint Capital, LLC | 40,906 | +21,620 (+112.10%) | 0.07% | $0 M | Nov 13, 2026 |
| 67 | AQR Capital Management LLC | 37,310 | -171,659 (-82.15%) | 0.06% | $0 M | Nov 16, 2026 |
| 68 | WINTON GROUP Ltd | 37,200 | +4,400 (+13.41%) | 0.06% | $0 M | Nov 12, 2026 |
| 69 | Engineers Gate Manager LP | 36,531 | New | 0.06% | $0 M | Nov 16, 2026 |
| 70 | Marex Group Ltd | 35,250 | 0 (0.00%) | 0.06% | $0 M | Nov 16, 2026 |
| 71 | Aigen Investment Management, LP | 33,858 | New | 0.06% | $0 M | Nov 16, 2026 |
| 72 | Jpmorgan Chase & Co | 29,803 | +7,195 (+31.83%) | 0.05% | $0 M | Nov 12, 2026 |
| 73 | Russell Investments Group, Ltd. | 27,847 | -622 (-2.18%) | 0.05% | $0 M | Nov 6, 2026 |
| 74 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 25,379 | +1,284 (+5.33%) | 0.04% | $0 M | Nov 16, 2026 |
| 75 | Invesco Ltd. | 24,943 | -1,913 (-7.12%) | 0.04% | $0 M | Nov 12, 2026 |
| 76 | MetLife Investment Management, LLC | 21,153 | -7,225 (-25.46%) | 0.03% | $0 M | Nov 16, 2026 |
| 77 | Barclays PLC | 20,845 | +2,238 (+12.03%) | 0.03% | $0 M | Nov 6, 2026 |
| 78 | Vanguard Global Advisers, LLC | 20,371 | +244 (+1.21%) | 0.03% | $0 M | Nov 13, 2026 |
| 79 | Centiva Capital, LP | 19,318 | New | 0.03% | $0 M | Nov 13, 2026 |
| 80 | LPL Financial LLC | 19,050 | -80 (-0.42%) | 0.03% | $0 M | Nov 6, 2026 |
| 81 | Alliancebernstein L.P. | 18,040 | 0 (0.00%) | 0.03% | $0 M | Nov 16, 2026 |
| 82 | Police & Firemen's Retirement System of New Jersey | 17,569 | 0 (0.00%) | 0.03% | $0 M | Nov 9, 2026 |
| 83 | Tower Research Capital LLC (TRC) | 17,306 | +12,316 (+246.81%) | 0.03% | $0 M | Nov 16, 2026 |
| 84 | Prelude Capital Management, LLC | 17,050 | -2,563 (-13.07%) | 0.03% | $0 M | Nov 16, 2026 |
| 85 | Manufacturers Life Insurance Company, The | 15,854 | +976 (+6.56%) | 0.03% | $0 M | Nov 13, 2026 |
| 86 | Susquehanna International Group, LLP | 15,614 | -24,766 (-61.33%) | 0.03% | $0 M | Nov 16, 2026 |
| 87 | BNP Paribas Financial Markets | 12,668 | +5,132 (+68.10%) | 0.02% | $0 M | Nov 12, 2026 |
| 88 | Jain Global LLC | 12,300 | -8,700 (-41.43%) | 0.02% | $0 M | Nov 16, 2026 |
| 89 | Voya Investment Management LLC | 11,469 | 0 (0.00%) | 0.02% | $0 M | Nov 10, 2026 |
| 90 | Wells Fargo & Company/mn | 11,160 | -43,436 (-79.56%) | 0.02% | $0 M | Nov 16, 2026 |
| 91 | Commonwealth Equity Services, LLC | 11,000 | 0 (0.00%) | 0.02% | $0 M | Nov 2, 2026 |
| 92 | Essential Partners LLC | 10,842 | +1,040 (+10.61%) | 0.02% | $0 M | Oct 14, 2026 |
| 93 | Brevan Howard Capital Management LP | 10,025 | New | 0.02% | $0 M | Nov 16, 2026 |
| 94 | Simplex Trading, LLC | 8,450 | +8,111 (+2392.63%) | 0.01% | $0 M | Nov 4, 2026 |
| 95 | New York State Common Retirement Fund | 7,900 | 0 (0.00%) | 0.01% | $0 M | Nov 17, 2026 |
| 96 | Royal Bank Of Canada | 6,294 | -1,469 (-18.92%) | 0.01% | $0 M | Nov 16, 2026 |
| 97 | Larson Financial Group LLC | 6,105 | New | 0.01% | $0 M | Nov 5, 2026 |
| 98 | Northwestern Mutual Wealth Management Co | 6,000 | New | 0.01% | $0 M | Nov 13, 2026 |
| 99 | Legal & General Group Plc | 4,490 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 100 | Ameritas Investment Partners, Inc. | 3,298 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
Mutual funds holding Protara Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.66 M | $6 M | 2.7% | <0.01% | +7.5% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 1.36 M | $5 M | 2.2% | <0.01% | +12% | Jun 30, 2026 |
| 🇺🇸 Columbia Small Cap Value Discovery FundColumbia Management Investment Advisers, LLC | 758,070 | $3 M | 1.2% | 0.12% | new | Jul 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 586,965 | $2 M | 0.95% | <0.01% | +12% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 569,271 | $2 M | 0.92% | <0.01% | +12% | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 475,364 | $2 M | 0.77% | 0.01% | +9.1% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 264,329 | $1 M | 0.43% | <0.01% | +51% | May 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 241,686 | $1 M | 0.39% | <0.01% | +32% | May 31, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 182,472 | $1 M | 0.30% | <0.01% | +23% | Jul 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 175,831 | $1 M | 0.29% | 0.04% | +36% | Jun 30, 2026 |
| 🇺🇸 Vanguard U.S. Momentum Factor ETFThe Vanguard Group, Inc. | 141,979 | $1 M | 0.23% | 0.04% | +20% | May 31, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 131,860 | $1 M | 0.21% | <0.01% | +82% | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 125,321 | $0 M | 0.20% | <0.01% | −30% | Jul 31, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 122,956 | $0 M | 0.20% | <0.01% | +8.9% | Jul 31, 2026 |
| 🇺🇸 Small Cap Value FundNorthern Trust Investments, Inc. | 117,674 | $0 M | 0.19% | 0.07% | new | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 91,844 | $0 M | 0.15% | 0.02% | +13% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 83,341 | $0 M | 0.14% | <0.01% | +42% | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 68,889 | $0 M | 0.11% | <0.01% | +41% | May 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 83,507 | $0 M | 0.14% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 78,000 | $0 M | 0.13% | 0.20% | +24% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 73,022 | $0 M | 0.12% | 0.01% | +14% | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 70,086 | $0 M | 0.11% | <0.01% | +14% | Jul 31, 2026 |
| 🇺🇸 ALPS Medical Breakthroughs ETFALPS Advisors, Inc. | 55,748 | $0 M | 0.09% | 0.16% | +21% | May 31, 2026 |
| 🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC | 65,107 | $0 M | 0.11% | 0.04% | +24% | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 51,733 | $0 M | 0.08% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 39,575 | $0 M | 0.06% | 0.01% | +54% | May 31, 2026 |
| 🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC | 44,729 | $0 M | 0.07% | <0.01% | +1672% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 31,457 | $0 M | 0.05% | <0.01% | +13% | May 31, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 35,000 | $0 M | 0.06% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Multi-Manager Small Cap Equity Strategies FundColumbia Funds Series Trust I | 27,260 | $0 M | 0.04% | <0.01% | new | May 31, 2026 |
| 🇺🇸 NVIT Multi-Manager Small Company FundNATIONWIDE FUND ADVISORS | 30,200 | $0 M | 0.05% | 0.03% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 28,387 | $0 M | 0.05% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 26,902 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 26,054 | $0 M | 0.04% | <0.01% | +9.6% | Jul 31, 2026 |
| 🇺🇸 NVIT Small Cap Value FundNATIONWIDE FUND ADVISORS | 26,300 | $0 M | 0.04% | 0.05% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 21,256 | $0 M | 0.03% | <0.01% | +59% | May 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 25,700 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 24,988 | $0 M | 0.04% | <0.01% | +12% | Jul 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 25,444 | $0 M | 0.04% | <0.01% | −2.6% | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 22,692 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP | 21,419 | $0 M | 0.03% | <0.01% | +38% | Jul 31, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 21,779 | $0 M | 0.04% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 20,174 | $0 M | 0.03% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Small Cap Equity FundGuideStone Capital Management, LLC | 19,600 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 19,061 | $0 M | 0.03% | <0.01% | +19% | Jul 31, 2026 |
| 🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP | 18,477 | $0 M | 0.03% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 17,400 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 16,303 | $0 M | 0.03% | <0.01% | −2.4% | Jun 30, 2026 |
| 🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP | 14,686 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 AQR Small Cap Momentum Style FundAQR CAPITAL MANAGEMENT, LLC | 10,978 | $0 M | 0.02% | 0.03% | — | Mar 31, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 13,318 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP | 11,973 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 11,866 | $0 M | 0.02% | 0.02% | +30% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 11,635 | $0 M | 0.02% | <0.01% | +23% | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 10,298 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 10,434 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 10,057 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 9,020 | $0 M | 0.01% | <0.01% | +259% | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 9,020 | $0 M | 0.01% | <0.01% | +259% | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 8,393 | $0 M | 0.01% | <0.01% | +17% | Jun 30, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 8,362 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 8,096 | $0 M | 0.01% | <0.01% | +17% | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Equity Market ETFDimensional Fund Advisors LP | 7,914 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 7,890 | $0 M | 0.01% | <0.01% | +38% | Jun 30, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 7,712 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 7,440 | $0 M | 0.01% | <0.01% | +38% | Jun 30, 2026 |
| 🇺🇸 U.S. Sustainability Core 1 PortfolioDimensional Fund Advisors LP | 7,228 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP | 6,250 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 6,128 | $0 M | <0.01% | <0.01% | +68% | Jul 31, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 6,087 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 5,824 | $0 M | <0.01% | <0.01% | +3.8% | Jul 31, 2026 |
| 🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP | 5,791 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 U.S. Social Core Equity 2 PortfolioDimensional Fund Advisors LP | 4,825 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 4,279 | $0 M | <0.01% | <0.01% | +140% | Jul 31, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 4,120 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 4,184 | $0 M | <0.01% | <0.01% | +56% | Jun 30, 2026 |
| 🇺🇸 Invesco Russell 2000 Dynamic Multifactor ETFInvesco Capital Management LLC | 3,365 | $0 M | <0.01% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 4,029 | $0 M | <0.01% | <0.01% | +25% | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity FundAmerican Century ETF Trust | 3,240 | $0 M | <0.01% | 0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 3,185 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Dimensional US Vector Equity ETFDimensional Fund Advisors LP | 3,715 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 3,764 | $0 M | <0.01% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 3,333 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 3,298 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC | 2,994 | $0 M | <0.01% | <0.01% | +24% | Jun 30, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 2,400 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 2,419 | $0 M | <0.01% | <0.01% | +58% | May 31, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 2,607 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 1,912 | $0 M | <0.01% | <0.01% | −12% | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 1,891 | $0 M | <0.01% | <0.01% | −13% | May 31, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 2,196 | $0 M | <0.01% | <0.01% | −33% | Jun 30, 2026 |
| 🇺🇸 SA U.S. Small Company FundFocus Advisor Solutions, LLC | 1,836 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 1,714 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC | 1,133 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 1,107 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 991 | $0 M | <0.01% | <0.01% | +32% | Jun 30, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 792 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 97 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Protara Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Jesse SheffermanCEO and President, Director | Gift | -14,000 | — | — | 707,832 | Form 4 |
| filed | Jesse SheffermanCEO and President, Director | Gift | -7,000 | — | — | 700,832 | Form 4 |
| filed | Jesse SheffermanCEO and President, Director | Gift | -4,000 | — | — | 696,832 | Form 4 |
| filed | Jesse SheffermanCEO and President, Director | Gift | -5,000 | — | — | 691,832 | Form 4 |
| filed | Jesse SheffermanCEO and President, Director | Option exercise | +215,687 | $1.910 | $412 K | 937,519 | Form 4 |
| filed | Jesse SheffermanCEO and President, Director | Sell | -215,687 | $4.090 | $882 K | 721,832 | Form 4 |
| filed | William ConklingChief Commercial Officer | Shares withheld for tax | -6,008 | $4.340 | $26 K | 69,992 | Form 4 |
| filed | Jacqueline ZummoChief R&D Officer | Sell10b5-1 plan | -1,134 | $5.400 | $6 K | 94,827 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Protara Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q1 2024 | Q1 2024 | $0.1M |
| Q4 2023 | Q4 2023 | $0M |
| Q3 2023 | Q3 2023 | $0M |
| Q2 2023 | Q2 2023 | $0M |
| Q1 2023 | Q1 2023 | $0.1M |
| Q4 2022 | Q4 2022 | $0M |
| Q3 2022 | Q3 2022 | $0M |
| Q2 2022 | Q2 2022 | $0M |
| Q1 2022 | Q1 2022 | $0.1M |
| Q4 2021 | Q4 2021 | $0M |
| Q3 2021 | Q3 2021 | $0M |
| Q2 2021 | Q2 2021 | $0M |
| Q1 2021 | Q1 2021 | $0.2M |
Trading halts
- 2024-12-05 14:44 UTC, code LUDP, resumed 14:54 UTC
Fails to deliver
- : 21 shares at $3.82
- : 1,248 shares at $3.97
- : 104 shares at $3.94
- : 5 shares at $3.81
- : 675 shares at $3.90
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Protara Therapeutics, Inc. scorecard#
Passes 1 of the 8 checks that could be worked out. Fiscal year 2025; market cap of Aug 1, 2026.
Valuationnot known
- –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
- –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
- –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-1.34 vs -2.17Diluted EPS -1.34 in fiscal 2025 against -2.17 the year before (report's currency).
- ✗Net income higher than five years earlier-$57 M-$57 M in fiscal 2025 against -$34 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$57 MNet income -$57 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-31.6%-31.6% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities14.6×Current ratio 14.58 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year108.0%Diluted shares up 108.0% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Protara Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Research and development | 43+34.5%— | 32+26.9%— | 25+48.7%— | 17−20.3%— | 21+76.0%— | 12+209%— | 3.9r6.4−67.3%— | 12−45.4%— | 22+14.9%— | 19—— | |
| General and administrative | 22+25.6%— | 17−6.3%— | 19−10.2%— | 21−21.5%— | 26+17.5%— | 22+468%— | 4.0r8.8−58.5%— | 9.5+9.8%— | 8.7−11.8%— | 9.8—— | |
| Operating expenses | 65+31.3%— | 49+12.7%— | 44−35.0%— | 67+41.2%— | 47+37.9%— | 34+340%— | 7.8r15−63.4%— | 21−29.6%— | 30+5.8%— | 29—— | |
| Operating income | −65—— | −49—— | −44—— | −67—— | −47—— | −34—— | −7.8r−15—— | −21—— | −30—— | −29—— | |
| Interest and finance income | 6.4+53.0%— | 4.2+30.6%— | 3.2+188%— | 1.1+368%— | 0.2−52.6%— | 0.5—— | — | — | — | — | |
| Interest expense and finance costs | — | — | — | — | 0−100%— | 0.0—— | — | — | — | — | |
| Net interest income | — | — | — | — | — | −0.0r0.5—— | — | — | — | — | |
| Other non-operating income (expense) | 7.1+56.0%— | 4.6+42.7%— | 3.2+188%— | 1.1+368%— | 0.2−49.1%— | 0.5+77.9%— | 0.3−59.3%— | 0.6+61.6%— | 0.4+122%— | 0.2—— | |
| Income before tax | 57+28.7%— | 45—— | — | — | — | — | −15—— | −21—— | −30—— | −29—— | |
| Net income including minority interests | — | — | — | — | −47—— | −34—— | −7.8—— | — | — | — | |
| Net income attributable to shareholders | −57—— | −45—— | −40—— | −66—— | −47—— | −34—— | −7.8r−15—— | −21—— | −30—— | −29—— | |
| Earnings per share, basic | -1.34—— | -2.17—— | -3.57—— | -5.86—— | -4.21—— | -4.70—— | -3.04r-30.15—— | -45.80r-1.15—— | -2.13—— | -1.72—— | |
| Earnings per share, diluted | -1.34—— | -2.17—— | -3.57—— | -5.86—— | -4.21—— | -4.70—— | -3.04r-30.15—— | -45.80r-1.15—— | -2.13—— | -1.72—— | |
| Shares, weighted average (basic) | 43+108%— | 21+81.7%— | 11+0.6%— | 11—— | — | — | — | — | — | — | |
| Shares, weighted average (diluted) | 43+108%— | 21+81.7%— | 11+0.6%— | 11+0.2%— | 11+55.3%— | 7.2+181%— | 2.6r0.5+470%— | 0.5r18−97.4%— | 17+4.3%— | 17—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 50−69.5%23.7% | 163+311%89.7% | 40+64.1%50.1% | 24−32.5%21.3% | 36−78.8%20.7% | 169+29793%83.0% | 0.6r6.2−97.1%46.1% | 19−8.5%82.4% | 21−41.8%48.1% | 36—83.6% | |
| Short-term investments | 106+1313%50.6% | 7.5−71.2%4.1% | 26−56.9%32.9% | 60+8.5%53.2% | 56—32.2% | — | — | — | — | — | |
| Other current assets | 0.1+3150%0.0% | 0.0−94.6%0.0% | 0.0−70.9%0.0% | 0.1+274%0.1% | 0.0−34.6%0.0% | 0.1r0.8−33.3%0.0% | 0.1r0.7−94.3%6.4% | 1.4+2.2%5.8% | 1.3−6.9%3.0% | 1.4—3.3% | |
| Current assets | 160−7.3%76.1% | 172+151%94.9% | 69−20.2%87.0% | 86−7.5%76.0% | 93−45.0%53.9% | 169+22077%83.4% | 0.8r7.0−96.7%62.5% | 23−46.6%98.8% | 43+1.7%98.9% | 43—98.2% | |
| Property, plant and equipment | 0.8−26.1%0.4% | 1.0−20.8%0.6% | 1.3−18.6%1.6% | 1.6−7.4%1.4% | 1.7+38.6%1.0% | 1.2+170%0.6% | 0.5r0.5+74.5%37.5% | 0.3+1.5%1.1% | 0.3−30.4%0.6% | 0.4—0.9% | |
| Right-of-use (leased) assets | 3.2−25.4%1.5% | 4.3−19.2%2.3% | 5.3−16.1%6.7% | 6.3−12.5%5.5% | 7.2+577%4.2% | 1.1—0.5% | — | — | — | — | |
| Goodwill | — | — | — | — | 300.0%17.1% | 30—14.5% | — | — | — | — | |
| Total assets | 209+15.4%100% | 181+130%100% | 79−30.3%100% | 113−34.4%100% | 173−15.0%100% | 203+16511%100% | 1.2r7.0−94.8%100% | 24−46.5%100% | 44+1.1%100% | 44—100% | |
| Accounts payable | 3.5−21.7%1.7% | 4.4+82.0%2.4% | 2.4+53.5%3.1% | 1.6+66.2%1.4% | 1.0+4.4%0.6% | 0.9+27.7%0.4% | 0.7r0.3+62.4%58.5% | 0.4+51.5%1.9% | 0.3−47.7%0.7% | 0.6—1.3% | |
| Debt due within a year | — | — | — | — | 0—0.0% | 0—0.0% | — | — | — | — | |
| Current liabilities | 11−0.2%5.2% | 11+78.3%6.0% | 6.1+7.1%7.8% | 5.7+33.6%5.1% | 4.3+47.4%2.5% | 2.9−13.0%1.4% | 3.4r0.6+8.9%274% | 3.1−66.7%13.1% | 9.2+81.9%21.0% | 5.1—11.7% | |
| Lease liabilities (non-current) | 2.1−37.0%1.0% | 3.4−25.1%1.9% | 4.5−18.0%5.7% | 5.5−14.4%4.8% | 6.4+539%3.7% | 1.0—0.5% | — | — | — | — | |
| Total liabilities | 13−8.8%6.2% | 14+34.7%7.9% | 11−5.1%13.5% | 11+4.9%9.9% | 11+173%6.2% | 3.9+16.8%1.9% | 3.4r0.6+8.9%274% | 3.1−66.7%13.1% | 9.2+81.9%21.0% | 5.1—11.7% | |
| Retained earnings | −302—−144% | −245—−135% | −200—−254% | −160—−141% | −94—−54.5% | −47—−23.0% | −13r−225—−1045% | −210—−895% | −190—−431% | −160—−367% | |
| Shareholders' equity | 196+17.5%93.8% | 167+145%92.1% | 68−33.1%86.5% | 102−37.0%90.1% | 162−18.7%93.8% | 199—98.1% | −2.1r6.4−145%−174% | 4.8r20−86.2%20.3% | 35r35−9.6%79.0% | 38—88.3% | |
| Total liabilities and equity | 209+15.4%100% | 181+130%100% | 79−30.3%100% | 113−34.4%100% | 173−15.0%100% | 203+16511%100% | 1.2r7.0−94.8%100% | 24−46.5%100% | 44+1.1%100% | 44—100% | |
| Shares outstanding | 54+52.9%— | 35+208%— | 11+0.9%— | 11+0.3%— | 11+0.2%— | 11+327%— | 2.6r0.6+446%— | 0.5r19−97.3%— | 18+6.5%— | 17—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | — | — | 0.1—— | |
| Share-based compensation | 3.8−7.2%— | 4.1−32.3%— | 6.1−8.9%— | 6.7−35.5%— | 10+6.3%— | 9.7+2199%— | 0.4r0.9−87.6%— | 3.4+6.3%— | 3.2−3.5%— | 3.3—— | |
| Cash from operating activities | −56—— | −36—— | −38—— | −26—— | −35—— | −23—— | −5.0r−16—— | −23—— | −22—— | −24—— | |
| Capital expenditure | −0.1—— | −0.1—— | −0.0—— | −0.1—— | −0.6—— | −0.9—— | −0.5r−0.0—— | −0.1—— | −0.0—— | −0.3—— | |
| Acquisitions, net of cash acquired | — | — | — | — | — | −3.7—— | — | — | — | — | |
| Cash from investing activities | −139−828%— | 19−63.9%— | 53+255%— | 15—— | −98−3564%— | 2.8—— | −0.5r2.5−103%— | 18—— | −16−181%— | 20—— | |
| Shares issued | — | — | — | — | — | 74r66—— | — | — | — | — | |
| Shares bought back | — | — | −0.1—— | −0.1—— | −0.2—— | — | — | — | — | — | |
| Cash from financing activities | 83−40.9%— | 140—— | −0.1—— | −0.1—— | −0.2−100%— | 189+37780%— | 0.5−83.2%— | 3.0−87.0%— | 23+10981%— | 0.2—— | |
| Exchange-rate effect on cash | — | — | — | — | — | — | — | — | 0.2—— | −0.1—— | |
| Change in cash | — | — | — | — | — | — | −13—— | −1.8—— | −15—— | −3.6—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 60+55.0%— | 17+75.2%— | 17+57.4%— | 14+48.3%— | 13*+38.2%— | 9.6+18.8%— | 11+68.6%— | 9.1+18.1%— | 9.5*+48.9%— | 8.1—— | 6.4—— | 7.7—— | 6.4*—— | |
| General and administrative | 25+19.1%— | 6.3+22.8%— | 6.4+9.5%— | 6.1+21.9%— | 6.0*+23.7%— | 5.2+21.3%— | 5.8+36.1%— | 5.0+21.3%— | 4.8*+3.3%— | 4.3—— | 4.3—— | 4.1—— | 4.7*—— | |
| Operating expenses | 85+42.5%— | 23+56.9%— | 23+40.6%— | 20+39.0%— | 19*+33.3%— | 15+19.7%— | 17+55.6%— | 14+19.2%— | 14*+29.6%— | 12—— | 11—— | 12—— | 11*—— | |
| Operating income | −85—— | −23—— | −23—— | −20—— | −19*—— | −15—— | −17—— | −14—— | −14*—— | −12—— | −11—— | −12—— | −11*—— | |
| Interest and finance income | 6.5+8.0%— | 1.5−2.4%— | 1.7+1.8%— | 1.8+6.8%— | 1.5*+31.7%— | 1.5+35.2%— | 1.6+41.6%— | 1.7+129%— | 1.2*+41.0%— | 1.1—— | 1.1—— | 0.8—— | 0.8*—— | |
| Net interest income | — | 1.3+21.9%— | 1.5+21.0%— | — | — | 1.1—— | 1.2—— | — | — | — | — | — | — | |
| Other non-operating income (expense) | 6.7−2.0%— | 1.5−2.4%— | 1.7+1.8%— | 1.8−16.4%— | 1.8*+14.8%— | 1.5+35.2%— | 1.6+41.6%— | 2.2+192%— | 1.5*+88.2%— | 1.1—— | 1.1—— | 0.8—— | 0.8*—— | |
| Net income attributable to shareholders | −78—— | −22—— | −22—— | −18—— | −17*—— | −13—— | −15—— | −12—— | −13*—— | −11—— | −9.5—— | −11—— | −10*—— | |
| Earnings per share, basic | — | -0.35—— | -0.36—— | -0.31—— | — | -0.31—— | -0.35—— | -0.29—— | — | -0.50—— | -0.45—— | -0.97—— | — | |
| Earnings per share, diluted | — | -0.35—— | -0.36—— | -0.31—— | — | -0.31—— | -0.35—— | -0.29—— | — | -0.50—— | -0.45—— | -0.97—— | — | |
| Shares, weighted average (basic) | 63+48.7%— | 63+48.7%— | 61+44.3%— | 58+41.3%— | — | 42+89.3%— | 42+99.1%— | 41+256%— | — | 22—— | 21—— | 11—— | — | |
| Shares, weighted average (diluted) | 63+48.7%— | 63+48.7%— | 61+44.3%— | 58+41.3%— | — | 42+89.3%— | 42+99.1%— | 41+256%— | — | 22—— | 21—— | 11—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 25—16.1% | 25+100%16.1% | 17−45.8%9.7% | 15−83.9%7.7% | 50−69.5%23.7% | 13−75.8%8.7% | 31−64.8%20.1% | 91+75.1%54.3% | 163+311%89.7% | 52—55.0% | 90—88.1% | 52—76.7% | 40—50.1% | |
| Short-term investments | 102—65.1% | 102−15.2%65.1% | 125+38.2%71.2% | 121+268%63.1% | 106+1313%50.6% | 120+304%83.0% | 91—57.8% | 33+1000%19.5% | 7.5−71.2%4.1% | 30—31.6% | — | 3.0—4.4% | 26—32.9% | |
| Other current assets | 0.0—0.0% | 0.0−91.3%0.0% | 0.2+195%0.1% | 0.0+6.3%0.0% | 0.1+3150%0.0% | 0.2+7167%0.2% | 0.1+1850%0.0% | 0.0+433%0.0% | 0.0−94.6%0.0% | 0.0—0.0% | 0.0—0.0% | 0.0—0.0% | 0.0—0.0% | |
| Current assets | 130—82.8% | 130−4.4%82.8% | 146+16.8%83.0% | 140+10.6%72.9% | 160−7.3%76.1% | 136+59.4%93.8% | 125+35.7%79.7% | 127+118%75.1% | 172+151%94.9% | 85—90.4% | 92—90.7% | 58—85.0% | 69—87.0% | |
| Property, plant and equipment | 1.6—1.0% | 1.6+90.9%1.0% | 1.3+44.5%0.7% | 0.7−32.3%0.3% | 0.8−26.1%0.4% | 0.8−25.3%0.6% | 0.9−23.0%0.6% | 1.0−18.5%0.6% | 1.0−20.8%0.6% | 1.1—1.2% | 1.2—1.2% | 1.2—1.8% | 1.3—1.6% | |
| Right-of-use (leased) assets | 2.3—1.5% | 2.3−33.1%1.5% | 2.6−30.1%1.5% | 2.9−27.6%1.5% | 3.2−25.4%1.5% | 3.5−23.5%2.4% | 3.7−21.9%2.4% | 4.0−20.4%2.4% | 4.3−19.2%2.3% | 4.5—4.8% | 4.8—4.7% | 5.0—7.4% | 5.3—6.7% | |
| Total assets | 157—100% | 157+8.2%100% | 176+12.2%100% | 192+13.9%100% | 209+15.4%100% | 145+53.7%100% | 157+54.4%100% | 169+147%100% | 181+130%100% | 94—100% | 102—100% | 68—100% | 79—100% | |
| Accounts payable | 4.9—3.1% | 4.9+7.9%3.1% | 4.7−12.0%2.6% | 4.0+74.5%2.1% | 3.5−21.7%1.7% | 4.5+96.3%3.1% | 5.3+283%3.4% | 2.3+138%1.4% | 4.4+82.0%2.4% | 2.3—2.4% | 1.4—1.4% | 1.0—1.4% | 2.4—3.1% | |
| Current liabilities | 14—9.2% | 14+45.2%9.2% | 13+36.5%7.6% | 8.9+27.1%4.6% | 11−0.2%5.2% | 9.9+14.7%6.9% | 9.8+72.8%6.2% | 7.0+27.6%4.2% | 11+78.3%6.0% | 8.6—9.2% | 5.6—5.6% | 5.5—8.1% | 6.1—7.8% | |
| Lease liabilities (non-current) | 1.1—0.7% | 1.1−53.7%0.7% | 1.5−46.8%0.8% | 1.8−41.3%0.9% | 2.1−37.0%1.0% | 2.4−33.4%1.7% | 2.7−30.4%1.8% | 3.1−27.7%1.8% | 3.4−25.1%1.9% | 3.7—3.9% | 3.9—3.9% | 4.2—6.2% | 4.5—5.7% | |
| Total liabilities | 16—9.9% | 16+25.7%9.9% | 15+18.2%8.4% | 11+6.4%5.6% | 13−8.8%6.2% | 12+0.4%8.5% | 13+30.4%8.0% | 10+3.6%6.0% | 14+34.7%7.9% | 12—13.1% | 9.6—9.4% | 9.7—14.3% | 11—13.5% | |
| Retained earnings | −364—−232% | −364—−232% | −342—−194% | −320—−167% | −302—−144% | −285—−197% | −272—−173% | −257—−152% | −245—−135% | −232—−247% | −221—−217% | −211—−310% | −200—−254% | |
| Shareholders' equity | 141—90.1% | 141+6.6%90.1% | 161+11.7%91.6% | 181+14.3%94.4% | 196+17.5%93.8% | 132+61.7%91.5% | 144+56.9%92.0% | 158+171%94.0% | 167+145%92.1% | 82—86.9% | 92—90.6% | 58—85.7% | 68—86.5% | |
| Total liabilities and equity | 157—100% | 157+8.2%100% | 176+12.2%100% | 192+13.9%100% | 209+15.4%100% | 145+53.7%100% | 157+54.4%100% | 169+147%100% | 181+130%100% | 94—100% | 102—100% | 68—100% | 79—100% | |
| Shares outstanding | 60—— | 60+55.4%— | 59+53.1%— | 55+42.7%— | 54+52.9%— | 39+87.0%— | 39+239%— | 39+237%— | 35+208%— | 21—— | 11—— | 11—— | 11—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 5.4+45.8%— | 1.6+51.6%— | 1.4+53.3%— | 1.4+63.5%— | 1.0*+15.4%— | 1.0+12.5%— | 0.9−15.1%— | 0.8−32.1%— | 0.9*−37.7%— | 0.9—— | 1.1—— | 1.2—— | 1.5*—— | |
| Cash from operating activities | −72—— | −18*—— | −15*—— | −21—— | −17*—— | −12*—— | −12*—— | −15—— | −9.3*—— | −8.4*—— | −7.7*—— | −10—— | −8.7*—— | |
| Capital expenditure | — | −0.7*—— | — | — | −0.0*—— | −0.0*—— | −0.0*—— | −0.0—— | 0*—— | −0.0*—— | — | — | 0*—— | |
| Cash from investing activities | 2.2—— | 26*—— | 18*—— | −15—— | −27*−220%— | −6.5*—— | −48*−1720%— | −58−353%— | 23*+55.0%— | −29*—— | 2.9*—— | 23—— | 15*—— | |
| Shares bought back | — | — | — | — | — | — | — | — | — | — | — | −0.1—— | 0*—— | |
| Cash from financing activities | 82−17.2%— | 0.4*+3069%— | −0.0*−425%— | 1.1−33.9%— | 81*−17.3%— | 0.0*—— | 0.0*−100.0%— | 1.7—— | 98*—— | 0*—— | 42*—— | −0.1—— | 0*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Where Protara Therapeutics, Inc. operates: 3 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 5 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office3 subsidiaries | — |
| 🇧🇲 Bermuda | 1 subsidiary | — |
| 🇮🇪 Ireland | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Protara Therapeutics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Mr. Shefferman | $2.7 M | $2.3 M | $1.4 M | $199 |
| 2024Mr. Shefferman | $1.8 M | $4.4 M | $1.1 M | $197 |
| 2023Mr. Shefferman | $1.9 M | $1.3 M | $1.2 M | $70 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Protara Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 1 · Material agreement 3 · Unregistered share sale 1 · Shareholder vote 3 · Results announced 11
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 6, 2026
Acquisitions and funding#
3 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2017 | $22 M | Private placement after listing | $10 to $50 million | 11 | equity, options | SEC |
| May 2014 | $30 M | No. 3 | $10 to $50 million | 22 | equity | SEC |
| Sep 2013 | $4 M | No. 2 | $2 to $10 million | 17 | equity, debt, options | SEC |
| Aug 2011 | $15 M | No. 1 | $10 to $50 million | 19 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Protara Therapeutics, Inc. compares in Biotechnology
- Market cap$235 M · higher than 46% of 726
- Price / book1.2× · lower than 75% of 534
- FCF yield-24.0% · higher than 40% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Protara Therapeutics, Inc.🇺🇸 | $235 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Aug 1, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Protara Therapeutics, Inc.? Verify and update this profile — free
Show Protara Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.